Opportunity Information: Apply for PA 06 212
Apply for PA 06 212
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Pilot Studies Oral Complications of Cancer Therapies (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Mar 3, 2006.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Independent school districts County governments City or township governments Private institutions of higher education For profit organizations other than small businesses Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Pilot Studies Oral Complications of Cancer Therapies (R21) funding opportunity (PA-06-212) is an NIH grant announcement jointly sponsored by the National Institute of Dental and Craniofacial Research (NIDCR) and the National Cancer Institute (NCI). It focuses on clinical research aimed at reducing both how often oral complications occur and how severe they become in people receiving cancer therapies. The central idea is to support smaller, early-stage clinical studies that can generate credible preliminary data, so investigators can later compete for larger, full-scale clinical research support at the R01 level.
The scientific and public health motivation behind the program is that cancer treatments can produce significant oral side effects that interfere with eating, speaking, infection control, treatment adherence, and overall quality of life. This opportunity is designed to move the field toward practical, evidence-based approaches that prevent these complications, lessen their intensity, or improve management strategies in real clinical settings. Because the mechanism is an R21, the expectation is not that applicants will deliver definitive, practice-changing trials immediately, but rather that they will conduct well-justified pilot or exploratory clinical research that clarifies feasibility, refines protocols, estimates effect sizes, and establishes the groundwork needed for a subsequent, more definitive R01 clinical study.
In terms of award structure, the funding instrument is a grant under the discretionary category, and the activity area is health. The announcement lists an award ceiling of $200,000, and it explicitly states there is no cost sharing or matching requirement. The opportunity is tied to CFDA numbers 93.121 (Oral Diseases and Disorders Research) and 93.395 (Cancer Treatment Research), reflecting the joint dental/oral health and oncology emphasis.
Eligibility is broad and includes a wide range of domestic applicant organizations such as public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (other than small businesses), state and local governments (including counties, cities, townships), special district governments, independent school districts, public and state-controlled higher education institutions, public housing authorities/Indian housing authorities, and federally recognized Native American tribal governments as well as other tribal organizations. Importantly, foreign institutions are eligible to apply, and eligible agencies of the Federal Government may also apply. This wide eligibility scope is consistent with NIH’s goal of encouraging diverse clinical research teams and settings capable of studying oral complications associated with cancer therapies.
Timing-wise, the opportunity was originally posted on March 3, 2006, and the listing notes multiple receipt dates rather than a single deadline, meaning applications were accepted on an ongoing cycle consistent with NIH standard submission dates (with details provided in the full announcement). The archive date is June 1, 2009, indicating the specific announcement is no longer active, though similar NIH initiatives may exist under newer announcements.
For applicants looking for the authoritative requirements, application instructions, and scientific scope details, the full announcement is linked at http://grants.nih.gov/grants/guide/pa-files/PA-06-212.html. The contact point provided for technical access issues is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV, which is specifically meant for problems accessing or linking to the funding announcement rather than scientific questions about project fit.
Frequently Asked Questions (FAQs)
What is the name and identifier of this grant opportunity?
The opportunity is titled "Pilot Studies Oral Complications of Cancer Therapies (R21)" and the NIH funding announcement number is PA-06-212.
Which NIH institutes sponsor this funding opportunity?
This announcement is jointly sponsored by the National Institute of Dental and Craniofacial Research (NIDCR) and the National Cancer Institute (NCI).
What is the main goal of the program?
The program supports clinical research intended to reduce both the frequency (how often) and severity (how bad) of oral complications in people receiving cancer therapies.
What kinds of problems is the program trying to address?
Cancer treatments can cause significant oral side effects that can interfere with eating and speaking, increase infection risk, disrupt adherence to cancer treatment, and reduce overall quality of life. This opportunity is aimed at moving toward practical, evidence-based approaches to prevent, lessen, or better manage these oral complications in real clinical settings.
What does "R21" mean in this announcement?
The R21 mechanism is meant for smaller, early-stage pilot or exploratory studies. The expectation is not a definitive, practice-changing clinical trial right away, but well-justified preliminary clinical research that generates credible early data.
How is this R21 expected to relate to later R01 clinical research?
The central idea is to fund early clinical studies that can establish feasibility, refine protocols, estimate effect sizes, and otherwise build the groundwork needed to compete later for larger, full-scale R01 clinical research support.
What types of studies are most aligned with this opportunity?
Clinical pilot or exploratory studies focused on preventing oral complications, reducing their intensity, or improving management strategies associated with cancer therapies, with an emphasis on producing credible preliminary data for future, larger clinical studies.
Is the focus specifically clinical research, or does it include other types of research?
Based on the listing, the focus is clinical research aimed at reducing the occurrence and severity of oral complications from cancer therapies and improving real-world management strategies.
What is the funding instrument and general activity area?
The funding instrument is a grant, categorized as discretionary, and the activity area is health.
What is the maximum award amount listed for this opportunity?
The announcement lists an award ceiling of $200,000.
Is cost sharing or matching required?
No. The listing explicitly states there is no cost sharing or matching requirement.
Which CFDA numbers are associated with this opportunity?
The opportunity is tied to CFDA 93.121 (Oral Diseases and Disorders Research) and CFDA 93.395 (Cancer Treatment Research), reflecting its joint dental/oral health and oncology emphasis.
Who is eligible to apply?
Eligibility is broad and includes domestic applicants such as public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), state and local governments (including counties, cities, and townships), special district governments, independent school districts, public and state-controlled higher education institutions, public housing authorities/Indian housing authorities, federally recognized Native American tribal governments, and other tribal organizations.
Are for-profit organizations eligible?
Yes. For-profit organizations are eligible to apply, except for small businesses (as stated in the listing: "for-profit organizations (other than small businesses)").
Are foreign institutions eligible to apply?
Yes. The listing states that foreign institutions are eligible to apply.
Can U.S. federal government agencies apply?
Yes. The listing indicates eligible agencies of the Federal Government may apply.
When was the opportunity posted?
The opportunity was originally posted on March 3, 2006.
Is there a single application deadline?
No. The listing notes multiple receipt dates rather than a single deadline, indicating applications were accepted on an ongoing cycle consistent with NIH standard submission dates (with full details in the announcement).
Is this specific funding announcement still active?
No. The archive date is June 1, 2009, which indicates this specific announcement is no longer active, even though similar initiatives may exist under newer NIH announcements.
Where can applicants find the full, authoritative announcement details?
The full announcement is available at: http://grants.nih.gov/grants/guide/pa-files/PA-06-212.html
Who should be contacted for technical problems accessing the announcement link?
For technical access issues (such as problems accessing or linking to the funding announcement), the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Is the listed contact meant for scientific questions about whether a project fits the program?
No. The listing specifies that the OER Webmaster contact is for problems accessing or linking to the announcement, not for scientific questions about project scope or fit.
Browse more opportunities from the same category: Education Health
Next opportunity: NIDCR Small Research Grants for Data Analysis and Statistical Methodology (R03)
Previous opportunity: Nutrition and Diet in the Causation, Prevention, and Management of Heart Failure (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 06 212
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 06 212) also looked into and applied for these:
| Funding Opportunity |
|---|
| Clinical Trials Oral Complications of Cancer Therapy (R21) Apply for PAR 06 213 Funding Number: PAR 06 213 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Cutting Edge Basic Research Awards (CEBRA) (R21) Apply for PAR 06 209 Funding Number: PAR 06 209 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Information Technologies and the Internet in Health Services and Intervention Delivery (R21) Apply for PA 06 224 Funding Number: PA 06 224 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Information Technologies and the Internet in Health Services and Intervention Delivery (R03) Apply for PA 06 225 Funding Number: PA 06 225 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Mechanisms of Alcohol Associated Cancers (R21) Apply for PA 06 270 Funding Number: PA 06 270 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Exploratory Grants for Behavioral Research in Cancer Control (R21) Apply for PA 06 351 Funding Number: PA 06 351 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Memory T Lymphocytes in Cancer Immunology (R21) Apply for PA 06 349 Funding Number: PA 06 349 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Building Translational Research in Integrative Behavioral Science (R21) Apply for PAR 06 355 Funding Number: PAR 06 355 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| In vivo Cancer Imaging Exploratory/Developmental Grants (R21) Apply for PA 06 371 Funding Number: PA 06 371 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Cancer Surveillance Using Health Claims based Data System (R21) Apply for PA 06 386 Funding Number: PA 06 386 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Developmental Projects in Complementary Approaches to Cancer Care (R21) Apply for PA 06 400 Funding Number: PA 06 400 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Studies of Energy Balance and Cancer in Humans (R21) Apply for PA 06 405 Funding Number: PA 06 405 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Phased Innovation Research in Cancer Prognosis and Prediction (R21/R33) Apply for PA 06 434 Funding Number: PA 06 434 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Phase II Developmental Research in Cancer Prognosis and Prediction (R33) Apply for PA 06 435 Funding Number: PA 06 435 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Development of Frontal Cortex and Limbic System and their roles in Drug Abuse or Mental Health (R21) Apply for PA 06 445 Funding Number: PA 06 445 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Abuse Dissertation Research Epidemiology, Prevention, Treatment, Services, and Women and Sex/Gender Differences (R36) Apply for PAR 06 476 Funding Number: PAR 06 476 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Behavioral and Integrative Treatment Development Program (R21) Apply for PA 06 487 Funding Number: PA 06 487 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 06 488 Funding Number: PA 06 488 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R21) Apply for PA 06 496 Funding Number: PA 06 496 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R03) Apply for PA 06 497 Funding Number: PA 06 497 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 06 212", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.